THYROCARENSEThyrocare Technologies LimitedHighNeutral
Announced Thu, 7 May · 19:24 IST

Audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.3%1-day move
₹472.50
prior close
₹493.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.2+5.4+5.2+3.0+1.3-0.1+1.2-0.5-2.4-0.7+10.1+14.2+10.9
Up moveDown movePending
AI summary

Thyrocare Technologies reported strong FY2026 results with standalone revenue of Rs. 774.27 Crores, up 22% from Rs. 633.10 Crores in FY2025. Consolidated revenue stood at Rs. 829.04 Crores, growing 21% year-on-year. Standalone profit after tax (PAT) jumped 55% to Rs. 148.81 Crores from Rs. 95.78 Crores, while consolidated PAT increased 79% to Rs. 162.86 Crores. The auditors M S K A & Associates LLP issued an unmodified (clean) opinion on both standalone and consolidated results. Exceptional items of Rs. 5.97 Crores were recorded, including Rs. 4.01 Crores from new labour code implementation (gratuity changes) and Rs. 1.96 Crores from capital restructuring costs. The board recommended a dividend of Rs. 7 per share.

Likely market impact

The company delivered robust double-digit revenue growth alongside even stronger profit growth, indicating improved operational efficiency. The clean audit opinion removes any concerns about financial reporting quality, which should boost investor confidence in the near term.